Market Pulse
Daily · Oct 7, 2026 · data.go.kr + ECOS
KOSPI
6,803.90
-137.49 (-1.98%)
KOSDAQ
898.43
-21.49 (-2.34%)
KOSPI 200
1,073.63
-22.20 (-2.03%)
USD/KRW
1,338.50
009420KOSPI·May 21, 2026
Imeroprubart��s best-in-class potential remains intact
Mirae Asset Securities published a company analysis report on HANALL BIOPHARMA CO. Co., Ltd. (009420) titled "Imeroprubart��s best-in-class potential remains intact".
Summary
Covers HANALL BIOPHARMA CO. Co., Ltd. (009420).
Covered stock
More on 009420
IMVT-1402 to regain focus from 2H26Mirae Asset Securities · Mar 13, 2026Promising batoclimab results heighten expectations for IMVT-1402Mirae Asset Securities · Sep 25, 2025Batoclimab phase 3 trial data announcedMirae Asset Securities · Mar 21, 20251Q25 to be a key inflection pointMirae Asset Securities · Feb 27, 2025